Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (121-130 of 323) with videos related to

Pageof 33
Sort By:
Plos One|September 24, 2020
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancerYuji Miyamoto, Marta Schirripa, Mitsukuni Suenaga, et al.
BMJ Oncology|January 31, 2025
Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date reviewAlberto Giovanni Leone, Stefania Bonadonna, Chiara Cassani, et al.
Cancer Discovery|June 22, 2016
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal CancerFilippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trialsAlessandra Boccaccino, Daniele Rossini, Alessandra Raimondi, et al.
Cancer Biology & Therapy|September 13, 2013
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacyFilippo Pietrantonio, Federica Perrone, Pamela Biondani, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2017
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Cancer Treatment Reviews|August 25, 2019
Gastric cancer: Translating novels concepts into clinical practiceMassimiliano Salati, Giulia Orsi, Elisabeth Smyth, et al.
Cells|September 5, 2020
Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance StudyUmberto Malapelle, Paola Parente, Francesco Pepe, et al.
The Oncologist|June 22, 2014
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxomaFilippo Pietrantonio, Claudia Maggi, Giuseppe Fanetti, et al.
The Oncologist|March 19, 2022
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino StudyGiovanni Fucà, Alessandra Raimondi, Michele Prisciandaro, et al.
Pageof 33

Showing results (121-130 of 323) with videos related to

Sort By:
Pageof 33
Plos One|September 24, 2020
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancerYuji Miyamoto, Marta Schirripa, Mitsukuni Suenaga, et al.
BMJ Oncology|January 31, 2025
Implications of hormonal carcinogenesis for transgender and gender-diverse people undergoing gender-affirming hormone therapy: an up-to-date reviewAlberto Giovanni Leone, Stefania Bonadonna, Chiara Cassani, et al.
Cancer Discovery|June 22, 2016
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal CancerFilippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, et al.
European Journal of Cancer (Oxford, England : 1990)|June 10, 2023
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trialsAlessandra Boccaccino, Daniele Rossini, Alessandra Raimondi, et al.
Cancer Biology & Therapy|September 13, 2013
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacyFilippo Pietrantonio, Federica Perrone, Pamela Biondani, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2017
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancerMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
Cancer Treatment Reviews|August 25, 2019
Gastric cancer: Translating novels concepts into clinical practiceMassimiliano Salati, Giulia Orsi, Elisabeth Smyth, et al.
Cells|September 5, 2020
Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance StudyUmberto Malapelle, Paola Parente, Francesco Pepe, et al.
The Oncologist|June 22, 2014
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxomaFilippo Pietrantonio, Claudia Maggi, Giuseppe Fanetti, et al.
The Oncologist|March 19, 2022
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino StudyGiovanni Fucà, Alessandra Raimondi, Michele Prisciandaro, et al.
Pageof 33